Why Moderna Stock Is Plummeting Today

Shares of Moderna (NASDAQ: MRNA) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m. ET and was down as much as 13.9% earlier in the day. The steep decline comes as the S&P 500 and Nasdaq Composite lost 0.4% and 1.1%, respectively.

The vaccine maker's shares tumbled following the resignation of a key U.S. Food and Drug Administration (FDA) official who oversaw vaccine approvals.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

The top FDA vaccine regulator leaves

Peter Marks, who led the FDA's Center for Biologics Evaluation and Research (CBER), resigned Friday. As the head of CBER, Marks was critical in the rapid approval of COVID-19 vaccines during the pandemic and, more recently, was heavily involved in the regulator's oversight of cutting-edge cell and gene therapies.

The resignation came amid pressure from Donald Trump's Health and Human Services Secretary, Robert F. Kennedy Jr., a known vaccine skeptic. Marks stated in his resignation letter that it was "clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies."

It's not a good sign for the industry

BMO Capital Markets analyst Evan David Seigerman called the resignation a "significant negative" for biotech and biopharma companies, especially vaccine manufacturers like Moderna. He explained that the "politicization of FDA runs counter to the agency's mission" and introduces major uncertainty for drugmakers. Moderna could see its vaccine development programs delayed as the FDA takes a less friendly or possibly hostile stance. I would avoid Moderna and other biotechs until a clearer picture emerges as to how the FDA seeks to move forward.

Should you invest $1,000 in Moderna right now?

Before you buy stock in Moderna, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $672,177!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of March 24, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.